Sinopharm
↗Beijing, China
Sinopharm is the largest state-owned pharmaceutical and healthcare group in China, operating under the State-owned Assets Supervision and Administration Commission (SASAC). The company maintains a comprehensive industry chain covering R&D, manufacturing, logistics, and retail. It is a Fortune Global 500 company and serves as the primary 'national team' for China's public health initiatives, including the development and global distribution of vaccines.
The group's core business is divided into several major segments: pharmaceutical distribution (Sinopharm Group Co., Ltd.), biopharmaceuticals (China National Biotec Group - CNBG), chemical pharmaceuticals, traditional Chinese medicine (TCM), and medical devices. Sinopharm is the largest pharmaceutical logistics provider in Asia, managing a network that serves over 700,000 customers and operates more than 10,000 retail pharmacies.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Vaccines, Distribution, and Retail
SIZE & FINANCIALS
Employees:10000+
Revenue:$80B-$85B
Founded:1998
Ownership:public
Status:operating
FUNDING
Stage:Public
Investors:SASAC (State-owned Assets Supervision and Administration Commission), Fosun Pharma (Strategic Partner/Investor)
STOCK
Exchange:HKEX
Ticker:1099.HK
Market Cap:$7.95B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Vaccines (Inactivated, mRNA), Small molecule, mAb, Blood products, TCM
Active Trials:95
Trial Phases:Phase 1: 12 | Phase 2: 25 | Phase 3: 19 | Phase 4: 10
FDA Approvals:40
EMA Approvals:15
CORPORATE STRUCTURE
Parent Company:SASAC (State-owned Assets Supervision and Administration Commission of the State Council)
Subsidiaries:Sinopharm Group Co., Ltd. (1099.HK), China National Biotec Group (CNBG), China National Medicines Corporation Ltd. (600511.SH), Sinopharm Accord (000028.SZ), China Traditional Chinese Medicine Holdings (0570.HK)
Key Partnerships:GE Healthcare (Medical imaging joint venture 'Sino Imaging'), Merck/MSD (Distribution of Molnupiravir in China), Lonza (Capsugel joint venture extension), Fosun Pharma (Strategic equity and R&D collaboration)
COMPETITION
Position:Leader
Competitors:Shanghai Pharmaceuticals, China Resources Pharmaceutical Group, BeiGene, Innovent Biologics, Pfizer, Roche
LEADERSHIP
Key Executives:
Bai Zhongquan - Chairman of the Board
Zhao Bingxiang - Chairman of Sinopharm Group (1099.HK)
Lian Wanyong - President and Executive Director
Board Members:Zhou Song, Ding Haiyun, Wei Shuyuan, Liu Haijian, Li Xiangrong
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Sinopharm. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.